Royce & Associates LP Eagle Pharmaceuticals, Inc. Transaction History

Royce & Associates LP

$10.5 Billion
Q3 2024

A detailed history of Royce & Associates LP transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 13,821 shares of EGRX stock, worth $8,016. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,821

Previous 13,821 -0.0%

Holding current value

$8,016

Previous $77,000 33.77%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.26 - $6.51 $58,877 - $89,974	13,821 New	13,821 $72,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $131,809 - $198,278	-8,666 Reduced 14.64%	50,548 $797,000
Q2 2023 Aug 07, 2023	BUY	$17.74 - $31.87 $205,464 - $369,118	11,582 Added 24.32%	59,214 $1.15 Million
Q1 2023 May 04, 2023	BUY	$25.06 - $34.09 $311,671 - $423,977	12,437 Added 35.34%	47,632 $1.35 Million
Q4 2022 May 23, 2023	SELL	$24.98 - $39.77 $310,676 - $494,619	-12,437 Reduced 26.11%	35,195 $1.03 Million
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $282,773 - $450,196	11,320 Added 47.41%	35,195 $1.03 Million
Q3 2022 Nov 03, 2022	SELL	$26.42 - $47.12 $173,051 - $308,636	-6,550 Reduced 21.53%	23,875 $631,000
Q2 2022 Aug 04, 2022	SELL	$41.26 - $51.35 $255,688 - $318,215	-6,197 Reduced 16.92%	30,425 $1.35 Million
Q1 2022 May 05, 2022	BUY	$44.58 - $52.6 $801,459 - $945,642	17,978 Added 96.43%	36,622 $1.81 Million
Q4 2021 Feb 07, 2022	BUY	$45.82 - $56.9 $89,990 - $111,751	1,964 Added 11.77%	18,644 $949,000
Q3 2021 Nov 10, 2021	BUY	$43.79 - $55.78 $38,622 - $49,197	882 Added 5.58%	16,680 $930,000
Q2 2021 Aug 06, 2021	BUY	$36.86 - $44.5 $27,350 - $33,019	742 Added 4.93%	15,798 $676,000
Q1 2021 May 10, 2021	BUY	$40.32 - $50.97 $96,848 - $122,429	2,402 Added 18.98%	15,056 $628,000
Q4 2020 Feb 08, 2021	SELL	$41.72 - $51.34 $2,711 - $3,337	-65 Reduced 0.51%	12,654 $589,000
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $927,202 - $1.28 Million	-25,046 Reduced 66.32%	12,719 $540,000
Q2 2020 Aug 07, 2020	SELL	$43.24 - $55.02 $600,257 - $763,787	-13,882 Reduced 26.88%	37,765 $1.81 Million
Q1 2020 May 12, 2020	BUY	$34.37 - $60.07 $57,088 - $99,776	1,661 Added 3.32%	51,647 $2.38 Million
Q4 2019 Feb 06, 2020	SELL	$54.32 - $64.31 $476,983 - $564,706	-8,781 Reduced 14.94%	49,986 $3 Million
Q3 2019 Nov 13, 2019	SELL	$53.25 - $59.98 $472,114 - $531,782	-8,866 Reduced 13.11%	58,767 $3.32 Million
Q2 2019 Aug 12, 2019	BUY	$46.61 - $58.45 $146,821 - $184,117	3,150 Added 4.89%	67,633 $3.77 Million
Q1 2019 May 09, 2019	BUY	$38.66 - $51.82 $1.06 Million - $1.42 Million	27,344 Added 73.63%	64,483 $3.26 Million
Q4 2018 Feb 11, 2019	SELL	$36.72 - $67.73 $142,987 - $263,740	-3,894 Reduced 9.49%	37,139 $1.5 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $50,520 - $63,565	758 Added 1.88%	41,033 $2.85 Million
Q2 2018 Aug 09, 2018	SELL	$51.25 - $76.62 $1.53 Million - $2.28 Million	-29,768 Reduced 42.5%	40,275 $3.05 Million
Q1 2018 May 14, 2018	SELL	$52.16 - $66.86 $1.11 Million - $1.42 Million	-21,291 Reduced 23.31%	70,043 $3.69 Million
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $1.16 Million - $1.43 Million	23,418 Added 34.48%	91,334 $4.88 Million
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $3.17 Million - $4.1 Million	67,916	67,916 $4.05 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.55M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account

Royce & Associates LP Eagle Pharmaceuticals, Inc. Transaction History